dr. woyach on btk inhibition and the mechanism of action of ibrutinib
Published 11 years ago • 2.2K plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
6:30
cll whiteboard #1: introduction & mechanisms of action of bcr signaling inhibitors
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
1:31
dr. woyach discusses progression on ibrutinib with the acquisition of resistance mutations
-
1:53
dr. woyach on using ibrutinib in combination therapies
-
2:05
dr. tendler on the mechanism of action of ibrutinib
-
1:17
dr. woyach discusses progression on ibrutinib with the acquisition of resistance mutations
-
1:39
dr. woyach on the role of acalabrutinib in cll
-
1:37
woyach on the safety profiles of btk inhibitors in cll
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
1:26
dr. woyach discusses peripheral lymphocytosis in patients with cll taking ibrutinib
-
0:38
dr. woyach on the role of btk in cll
-
5:30
rationale for btk inhibition in cll
-
1:33
dr. woyach on ongoing research with btk inhibitors in cll
-
1:47
dr. woyach on ibrutinib resistance in cll
-
22:36
progress with btk inhibitors: a journey through the mechanisms of covalent and noncovalent options
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll
-
1:16
dr. woyach on ibrutinib and peripheral lymphocytosis in patients with chronic lymphocytic leukemia
-
5:59
differentiating btk inhibitor mechanisms of action in mcl
-
3:36
distinguishing features among btk inhibitors